Clinical reference Biomarker Directory
Back to directory

Lactate dehydrogenase

Established

LDH is a nonspecific cell-damage marker with specific, well-established prognostic value in lymphoma staging.

Also known as LDH lactic dehydrogenase
In plain language

LDH is a very general marker of cell damage found throughout the body, but in cancer care, it has a specific and important use: predicting how aggressive a lymphoma is likely to be, and warning doctors ahead of time about the risk of a dangerous complication called tumor lysis syndrome.

Biomarker & context

Lactate dehydrogenase (LDH) is an enzyme found in nearly all body tissues that catalyzes the conversion between lactate and pyruvate; its elevation is a general, nonspecific marker of cell damage, but carries specific prognostic importance in oncology.

What it indicates

Elevated LDH reflects tissue damage from hemolysis, tumor cell turnover, or organ injury; in oncology, it is a core component of the International Prognostic Index (IPI) for non-Hodgkin lymphoma, where elevated pretreatment LDH independently predicts worse outcomes across essentially all lymphoma subtypes.

Diagnosis & clinical testing

Measured via serum assay; LDH is also a key pretreatment risk marker for tumor lysis syndrome, a dangerous complication of treating bulky, fast-growing cancers, and total serum LDH activity more than twice the upper limit of normal correlates with increased risk of CNS involvement in lymphoma.

Guiding treatment

LDH is tracked during chemotherapy for early relapse detection in lymphoma, since a rise before imaging shows changes can sometimes be an early warning sign; markedly elevated pretreatment LDH also prompts closer monitoring and prophylaxis for tumor lysis syndrome during induction therapy.

Clinical significance

Core component of the International Prognostic Index (IPI); also predicts tumor lysis syndrome risk before treatment.

References
  1. PMC. (2013). The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma.
  2. Medscape. Tumor Lysis Syndrome: Practice Essentials.